Filing Flows › Nuvation Bio (NUVB) › Q1 2026
Nuvation Bio (NUVB) Q1 2026 earnings results (first quarter 2026)
10-Q filed May 4, 2026
Nuvation Bio (NUVB) reported revenue of $83.2M for the first quarter 2026 (Q1 2026), up 27-fold from a year earlier and +99% from the quarter before. Operating margin was 4.7%, net earnings $5.4M (6.5% of revenue).
Nuvation Bio, Q1 2026: revenue $83.2M (27× year over year), operating margin 4.7%, net earnings $5.4M, operating cash flow $5.1M. The chart follows the revenue to costs, profit and cash.
| Q1 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $83.2M | +99% | 27× |
| Operating profit | $3.9M | — | — |
| Net earnings | $5.4M | — | — |
| Operating cash flow | $5.1M | — | — |
What changed
Revenue was $83.2M in Q1 2026, up 2599% year over year and up 99% from the previous quarter. License was the largest line at 78% of revenue. License added $61.6M year over year (up 1999%), 77% of the total change.
Operating profit was $3.9M, a 4.7% margin (up 1917.9 points year over year). The fastest-growing cost line was Research & development (+42%). Net earnings were $5.4M. The effective tax rate was 0.0%. Non-operating items added $1.5M, 28% of pre-tax earnings, so the bottom line overstates operating performance.
Operating cash flow was $5.1M, 94% of net earnings. Non-cash charges added back $536K of depreciation and amortization and $9.0M of share-based compensation. Working capital and other items used $9.9M.
Questions
What was Nuvation Bio's revenue in the first quarter 2026?
Nuvation Bio (NUVB) reported revenue of $83.2M for the first quarter 2026 (Q1 2026), up 27-fold from a year earlier and +99% from the quarter before.
Was Nuvation Bio profitable in the first quarter 2026?
Operating profit was $3.9M (4.7% of revenue) and net earnings $5.4M.
Source: Nuvation Bio 10-Q on SEC EDGAR.